Baylor College of Medicine Cancer Center-Cancer Center Support Grant

贝勒医学院丹L邓肯综合癌症中心 总体-项目摘要 这是Dan L邓肯综合癌症中心的第三次CCSG竞争性更新申请 （DLDCCC）在贝勒医学院（Baylor College of Medicine，休斯敦，德克萨斯州）。休斯顿是美国第四大城市， 美国人口非常多样化，哈里斯县是美国人口增长最快的县之一。 国家DLDCCC集水区已从哈里斯县的核心扩大到包括8个 休斯顿大都会统计区（MSA）的周边县，代表了 超过700万人的多样化人口（这一人口超过35个国家）。的 DLDCCC是一个矩阵中心，与4家医院附属机构，德克萨斯儿童医院， DeBakey退伍军人事务医疗中心，Ben Taub医院和新的贝勒圣卢克医疗中心 作为正式的附属机构。DLDCCC于2007年获得NCI认证，并于2014年获得全面认证 通过我们的评估和规划流程以及我们的EAC和内部 自成立以来，我们在加强科学计划方面取得了重大进展。53例新发癌症 教师已被招募到DLDCCC，现在有192个研究成员，78个临床成员， 18个附属成员。我们的癌症相关同行评审研究资金现在超过1.69亿美元， 超过4900万美元（直接3400万美元）来自NCI。一些重要的科学成就 这对我们的流域和全球产生了影响。DLDCCC包括7项研究 项目：细胞信号传导和代谢，癌症演变机制，核受体，转录 染色质生物学，乳腺癌，癌细胞和基因治疗，癌症预防和人口 科学和儿科癌症。重大投资加强了10个共享资源， 提供领先的技术。先进体内癌症模型中的新共享资源进一步增强了我们的 能力的临床方案和数据管理核心得到了显著增强， 临床试验增加了。少数种族和族裔的应计费用尚未支付。外联办公室 和健康差异，推动COE向社区传播新的信息和服务， 尤其是那些得不到充分服务的人培训和教育已通过CRCE纳入我们的方案 核心在这次更新中，我们要求为我们的10个共享资源和其他扩展活动增加资金 对我们的使命和目标很重要。

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT SUMMARY This is the 3nd CCSG competitive renewal application of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM) in Houston, Texas. Houston is the 4th largest city in the United States with a very diverse population and Harris County is one of the most rapidly growing in the country. The DLDCCC Catchment Area has expanded from the core of Harris county to include the 8 surrounding counties which comprise the Houston Metropolitan Statistical Area (MSA), representing a diverse population of more than 7 million individuals (this population is greater than 35 states). The DLDCCC is a matrix center with BCM as the lead partner with 4 hospital affiliates, Texas Children’s, the DeBakey Veterans Affairs Medical Center, Ben Taub Hospital, and the new Baylor St. Luke’s Medical Center as formal affiliates. The DLDCCC received NCI designation in 2007 and comprehensive designation in 2014 and through our evaluation and planning process and recommendations from our EAC and internal committees, we have since made significant progress strengthening our scientific programs. 53 new cancer faculty have been recruited to the DLDCCC which now has 192 Research members, 78 Clinical members and 18 Adjunct members. Our cancer-relevant peer reviewed research funding now exceeds $169 million, with more than $49 million ($34M direct) coming from the NCI. Several important scientific accomplishments have been made that have an impact in our Catchment Area and globally. The DLDCCC comprises 7 research programs: Cell Signaling and Metabolism, Mechanism of Cancer Evolution, Nuclear Receptor, Transcription and Chromatin Biology, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Significant investments have strengthened the 10 Shared Resources, which offer leading technologies. A new shared resource in Advanced In Vivo Cancer Models further enhances our capabilities. The Clinical Protocol and Data Management Core has been significantly enhanced and accruals to clinical trials have increased. Accrual of racial and ethnic minorities is outstanding. The Office of Outreach and Health Disparities which drives COE disseminates new information and services to the community, especially the underserved. Training and education have been integrated into our Programs through the CRCE core. In this renewal, we ask for increased funding for our 10 Shared Resources and other expanded activities important to our mission and goals.